Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Tool, Dx Stocks Outperformed Pharma, Biotech in December, Report Shows

NEW YORK, Dec. 7 (GenomeWeb News) - Shares in genomic-based diagnostics and tools companies outperformed big drug makers and firms in other healthcare industry segments, according to a Pacific Growth Equities report analyzing stocks in the healthcare industry.


The weighted average total return of 109 diagnostic- and tool-company stocks analyzed by the investment bank increased 9.44 percent in December, compared with 7.66 percent for 151 medical technology stocks; 7.54 percent for 303 drugs stocks; 6.37 percent for nine "ancillary" stocks; and 5.65 percent for 71 services stocks.


Diagnostics and tools stocks included companies such as Applied Biosystems, whose shares increased 2 percent during the month; Cepheid, whose shares increased 7.93 percent; Charles River Labs, whose shares increased 1.58 percent; Ciphergen, whose shares increased 33.54 percent; Harvard Biosciences, whose shares increased 16.92 percent; Illumina, whose shares increased 24.74 percent; Invitrogen, whose shares increased 10.96 percent; Strategene, whose shares increased 5.56 percent; and Third Wave Tech, whose shares increased 6.7 percent.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.